ARTICLE | Clinical News
APD668: Interim Phase I data
January 14, 2008 8:00 AM UTC
Arena partner Johnson & Johnson placed development of APD668 on hold to focus on a more potent compound that is in preclinical development. The companies did say that in the APD668 Phase I program, wh...